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Identification of a transforming growth factor beta-i activator derived
from a human gastric cancer cell line
M Horimoto. J Kato. R Takimoto. T Terui. Y Mogi and Y Niitsu
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Summarv It has been shown that some types of tumour cells produce actixated transforming grou-th factor
beta-i (TGF-I1). How-ever. the mechanism for the actix-ation of TGF-i1 denived from tumour cells has not
been fullv elucidated The present study w-as undertaken to characterise an activator of latent TGF-i1 secreted
from a human gastric cancer cell line. KATO-I11 Western blot analyses using antibodies for TGF-pI. latency
associated peptide (LAP) and latent TGF-0l-binding protein (LTBP) revealed that. in the cell l-sate of
KATO-11. TGF-j31 protein A-as expressed as a small latent complex of TGF-P1 and LAP. This %-as also
confirmed by a gel chromatographic analy-sis of the cell l-sate obtained from KATO-I11 A 2.5 kb transcnrpt of
TGF-~l mRNA w-as detected in KATO-III cells by Northern blot anal-sis. A gel chromatographic analy-sis of
the conditioned medium from KATO-III cells revealed. in addition to the active form of TGF-01. a factor
w-hich actix-ated latent TGF-01 from NRK-49F cells at fractions near a molecular size of 65 000 This factor
>-as inacti-ated by heat (100TC). acidification. trvpsin and serine protease inhibitors. TGF-i1 actixity in
KATO-II1 cell IN-sate was not detected in the untreated state. but potent TGF-fl activity was detected after
acid treatment. These results suggest that KATO-I11 releases not only a latent TGF-PI complex but also a
type of senine protease. different from plasmin. plasminogen activator. cathepsin D. endoglycosidase F or
sialidase. which activates the latent TGF-I1 complex as effectivelv as acid treatment.
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Transforming grouth factor beta-I (TGF-Pl). initialiv found
as a transforming cytokine in tumour cells. is now- know-n to
exert multiple functions includinz immunosuppression. fibro-
sis of tissue. myelosuppression. osteozenesis. angiogenesis.
liver regeneration and mammalian development. It is usually
secreted in an inactive form and subsequently activated at the
site w-here it functions. The mechanism for this activation is
thought to result from its modulation by plasmin (L-ons et
al.. 1988: Sato and Rifkin. 1989). cathepsin D (Lyons et al..
1988). endogl-cosidase and sialidase (Mivazono and Heldin.
1989). Usuallx-. intracellular TGF-P1 exists as a latent form
which is composed of mature TGF-B1. amino-terminal rem-
nant of TGF-i1 precursor called latency associated peptide
(LAP) and latent TGF-0l-binding protein (LTBP). and w-ide
LAP-TGF- 1 complexes show- no TGF-pl activitx. From
certain types of tumour cells or normal diploid cells. how-
exer. an active form of TGF-PI from which LAP has been
released is secreted into culture medium either spontaneously
or on stimulation with vanous agents. However. few detailed
studies have been devoted to the question of w-hether the
active TGF-PI in the culture medium is actually released in
an active form or is released in a latent form together xvith
some activators. Takiuchi et al. (1992) demonstrated that a
particular type of Rous sarcoma virus-induced fibrosarcoma
cells have in their conditioned medium the potential to con-
vert latent TGF-PI to its active form. however the mech-
anism of its conversion has not been clarified. The present
study-. for the first time. demonstrates that KATO-ITI cells
derived from human gastric carcinoma secrete a senine pro-
tease. different from plasmin. plasminogen actixvator. cathep-
sin D. endoglvcosidase F or sialidase which activates a small
latent TGF-pl complex co-secreted from the same cells.
Materials and methods
Cell culture
A human scirrhous gastnc cancer cell line. KATO-III
(Sekiguchi et al.. 1978). >-as provided by Dr Daizo Saito of
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National Cancer Center. Tokyo. Japan. N-RK-49F cells u-ere
obtained from the Cell Bank of the Japan Scientific Research
Institute. Tokyo. Japan. KATO-II cells u-ere grow-n in
RPMI-1640 w-ith 10o fetal calf serum (FCS; Flou- Labor-
atories. McLean. VA. USA). N-RK-49F cells were grow-n in
minimum essential medium (MEM: Gibco. Grand Island.
NY. USA) with 50o calf serum (CS: Flou Laboratories).
Each cell line w-as maintained in the medium supplemented
w-ith 100 U ml-' of penicillin G. 2 mN' L-zlutamine and
100 pg ml- of kanamycin sulphate in tissue culture flasks
(Falcon No. 3024. Becton Dickinson. San Jose. CA. USA).
.4ntibodies
Anti-TGF- 1 antibodies wxere prepared as descnrbed prev-
iously (Terui et al.. 1990). In brief. synthetic peptides of the
1 - 1. 17-29 and 92-103 residues of the amino acid
sequence of the numbering of the mature 112 amino acid
TGF-PI (Derynk et al.. 1985) were svnthesised and immun-
ised to rabbits. The antisera A-ere heat-inactix-ated (56°C.
30 min). and IgG w-ere prepared from these antisera by pass-
ing through protein A-Sepharose (Pharmacia Biotechnology.
Uppsala. Sweden). Amonz these three. anti-N 92-103
antibodies were used as a neutralising antibody and anti-N
1 -15 antibodies for detection of TGF-1I (Terui et al.. 1990)
in cell extracts by Aestem blot analy-sis as described below-.
Anti-LAP and anti-LTBP antibodies (MiNazono et al.. 1991)
w-ere kindly provided by Dr K Miyazono. Ludw-iz Institute.
Uppsala. Sw-eden.
UWestern blot oft TGF-f. L.4P and LTBP
To prepare cell extracts from KATO-II cells. 1 x 10 cells
wxere homozenis'ed in phosphate-buffered saline containing
1 m-M phenylmethylsulphonyl fluoride (PMSF) with a Dounce
homozeniser (Wheaton Glass. Millivile. NJ. USA). Acid-
ethanol treatment of the cellular extract was performed as
previously described (Terui et al.. 1990). The protein con-
centration of the acid-ethanol soluble fraction xvas deter-
mined bv a bicinchoninic acid protein assay (Pierce. Rock-
ford. IL. USA). and then a 10 g aliquot wvas analysed by
12.50o or 4-200o gradient sodium dodecylsulphate pol--
acrylamide gel electrophoresis (SDS-PAGE) either under
reducing or non-reducing conditions according to the
method of Laemmli (1970). Proteins in the gels were elect-rophoretically transferred onto Immobilon-P membranes
(Millipore. Bedford, MA. USA). Each membrane was pro-
bed with anti-TGF-0l antibodies. anti-LAP antibody and
anti-LTBP antibody. The antigen-antibody complex was
visualised using an ABC-kit (Vector Laboratories. Burlin-
game. CA. USA) or an ECL-kit (Amersham. Buckingham-
shire. UK).
Northern blot
The total RNA fraction was extracted from cells bv acidic
guanidiium thiocyanate-phenol chloroform according to the
method of Chomczy-nski and Sacchi (1987). An aliquot of
10 ig of total RNA was denatured with formamide and
formaldehyde. and was electrophoresed onto a 1% agarose
gel. With use of a transblot electrophoresis apparatus (Trans-
blot Apparatus. Bio-Rad. Richmond. VA. USA). the RNA
was transferred from the gel to a nylon filter (Zeta-Probe
blotting membrane. Bio-Rad). The EcoRI-PstI restriction
fragment (1572 bp) of TGF-B1 cDNA clone derived from a
human nasopharynzeal carcinoma. KB cell (Urushizaki et
al.. 1987) was labelled with [x-3'2PdCTP (Amersham) by ran-
dom hexamer priminz (Feinberg and Vogelstein. 1984) and
was used as a probe. The filter was then submerged in
hvbridisation buffer (400/o formamide. 4 x SCC. 50 mM N-(2-
hydroxyethyl)piperazine-.N'-2-ethanesulphonic acid (Hepes)
buffer. 10 x Denhardt's solution. 1001agml-' denatured
salmon sperm DNA. pH 7.4. to which the 32P-labelled cDNA
probe had been added. and incubated at 42°C for 18 h. After
hybridisation. the filter was washed and autoradiographed as
described elsewhere (Terui et al.. 1990).
Preparation ofconditioned mediumfrom KATO-III and
NRK-49F cells
Conditioned medium from KATO-III cells was prepared as
previously reported (Terui et al.. 1990). In this process. the
pH of the conditioned medium from KATO-I1I cells was
never allowed to fall below pH 6.0 so that latent TGF-PI
would not be activated. The conditioned medium from
NRK49F cells which was used as the source of latent TGF-
P1 was prepared by a partial modification of the method of
Lyons et al. (1990). Briefly. the cells were cultured in 15 ml of
MEM containing 5% CS in 75 cmI tissue culture flasks.
After reaching confluence. the cells (2 x 106 cells per flask)
were washed in serum-free MEM, incubated in 6 ml of the
same medium for 24 h at 37'C under 5% carbon dioxide-air,
and centrifuged to recover the supematant which was used as
the conditioned medium from NRK49F cells.
Preparation ofcell lv sate
KATO-III cells (1 x 10) were suspended in 1.0 ml of 10 mM
sodium phosphate buffer. pH 7.4, 150 mM sodium chloride,
1 mM phenylmethylsulphonyl fluoride (PMSF), homogenised
with a Dounce homogeniser. and then centrifuged at
100 000 x g for 30 min to remove cell debris. The super-
natant was recovered and used as the lysate. To activate
latent TGF-1 in the lysate. hydrochloric acid was added to
the supernatant to obtain a final concentration of 115 mm
(pH<3.0). After incubating for 1 h at 4'C. it was neutralised
with an equivalent quantity of sodium hydroxide.
Soft agar colony assay of TGF-fJ activity
According to the method of Roberts et al. (1990). 1.0 ml
aliquots of Dulbecco's modified Eagle medium (DMEM)
containing 10% FCS with 0.5% agar was solidified in six-
well culture plates (Falcon. no. 3046. Becton Dickinson).
Over the basal layer of this preparation, 9 x I03 NRK49F
cells in 1.Oml of MEM containing 0.3% agar. 1.Ongml-'
epidermal growth factor (Nakarai. Tokyo, Japan). and 0.1 ml
of conditioned medium or 50 jig of cell lysate was added and
hardened. Cultures were incubated for 7 days at 37'C under
TGF-p1 activator-erved gastric cance cefl
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500 carbon dioxide -air and the number of colonies per well
was counted.
Radioreceptor assaY for TGF-PI
According to the method of Frolik et al. (1984). 1 x 10; of
NRK-49F cells were plated and incubated for 24 h on 24-
well microplates (Falcon. no. 3047. Becton-Dickinson). The
cultures were then washed with MEM containing 0.11%
bovine serum albumin and 25 m-m Hepes. pH 7.4. to remove
the ligands. Next. '--labelled TGF-P1 (specific activity 558
MBq mmol I -'. Amersham. Tokyo. Japan) providing a final
concentration of 0.25 ng ml-'. and the samples were added.
The plates were incubated for 3 h at 4C. After the cells were
w-ashed. they were solubilised w-ith 10 Triton X-100. 1000
glycerol. 20 mm Hepes. 150 mm sodium chloride. pH 7.4.
The radioactivity was measured with a y-counter (Pharmacia
Biotechnology. Uppsala. Sweden).
En:Yme-linked immunosorbent assay (ELIS4A X for TGF-PI
To determine immunoreactive TGF- 1 in the conditioned
medium of NRK-49F cells. a TGF-P1 ELISA kit (Amer-
sham. Tokyo. Japan) was used according to the manu-
facturer's instructions. and the absorbance at 492 nm was
measured spectrophotometrically.
Gel chromatography
An aliquot of 0.5 ml of conditioned medium or cell lysate
prepared from KATO-I1I cells was fractionated (0.5 ml per
tube) by gel chromatography on a SW3.000 column (Toyo
Soda. Tokyo. Japan) using phosphate-buffered saline as
eluent. Aliquots of 0.1 ml of the individual fractions. either
alone or after addition of 0.1 ml of NRK49F conditioned
medium containing latent TGF-P1. were then incubated for
60 mn at 37C. after which TGF-PI activity was measured
bv soft agar colony assay and radioreceptor assay.
Phvsicochemical and enzymatic treatments of TGF-PI
activator
The physicochemical properties of the TGF-fi1 activator were
investigated by using crude fractions of the TGF-P1 activator
obtained by the gel chromatography of conditioned medium
from KATO-II1 cells. Heat treatment of the TGF-PI
activator was performed by maintaining it at 56°C for 30 mn
or at 100°C for 5 mmn. Acid treatment was performed by
titration with hydrochloric acid to pH 1.5 or pH 4.0 and
neutralised with sodium hydroxide after incubating for 2 h.
Trypsin (type TI-S. Sigma. St. Louis, MO. USA) treatment
was performed by adding the enzyme to achieve a final
concentration of 0.25% and allowing the sample to incubate
for 30 min at 37C. followed by neutralisation with soybean
trypsin inhibitor (type I-P, Sigma). Treatment of the TGF-PI
activator with various protease inhibitors was performed by
adding a final concentration of 1 mM nafamostat mesilate
(Torii. Tokyo, Japan), 1 mM diisopropyl fluorophosphate
(DFP). 1 mM PMSF. 0.5 mM N-ethylmaleimide (Sigma).
1 U ml-' a-plasmin inhibitor (Sigma), 21g ml-1 pepstatin
(Sigma) or 2 mM ethylenediaminetetraacetic acid (EDTA)
(Sigma), followed by incubation for 60mn at 37C. After
undergoing each type of physicochemical treatment. 0.1 ml of
the fraction containing TGF-PI activator was incubated for
60 min at 37°C with 0.1 ml of NRK-49F conditioned medium
containing latent TGF-PI and the TGF-PI activity was then
measured by radioreceptor assay. Next, we determined the
activity of TGF-P1 activator against a latent form ofTGF-PI
derived from NRK49F cells comparing some enzymes which
have been reported to activate latent TGF-pl. Each 0.1 ml of
NRK49F conditioned medium was treated with 1.0 U ml-'
plasmin from human plasma (Sigma), 0.3 U mll cathepsin D
(Sigma), 0.5 U ml-' endoglycosidase F or 0.5 U ml-' sial-
idase (Sigma) for 60 mmn at 37'C and then immunoreactiveTG*41 acbvalor-dwivW gastric cancer ceU
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mature TGF-P1. considered as an active form, was deter-
mined bv ELISA.
Plasmin activitY
Plasmin activity was assessed by the method of Friberger et
al. (1978) with some modifications. Briefly, 200 g ml-' pro-
tein including the TGF-P1 activator (Figure 3b, peak 2) was
incubated with 800 g ml-' chromogenic plasmin substrate
NS-1 100 (Nittho Bouseki. Tokyo, Japan) on 37C for
3 min after which the reaction was stopped by adding of
0.1 mM acetic acid. The hydrolytic substrate was then
measured at 405 nm spectrophotometrically against a blank.
Results
Expression of TGF-01. LA.P and LTBP in KA TO-III cells
The expression of TGF-pl. LAP and LTBP protein in the
cell lysate of KATO-III cells was investigated by Western
blot analyses. As shown in Figure la. by a Western blot
using anti-TGF-Pl antibodies. TGF-PI was detected at a
molecular mass of 52.5 kDa under reducing conditions
when the cellular extract of KATO-III was loaded before
treatment with acid-ethanol (lane 1). Following treatment
of the cellular extract with acid-ethanol. TGF- I was
visualised at a position of 12.5 kDa under reducing cond-
itions. corresponding to the TGF-01 monomer (lane 2). In
addition. a band in the lysate of KATO-III cells detected by
the anti-TGF-PI antibody migrated at the same molecular
size as that detected by anti-LAP antibody (lane 3).
indicating that TGF-P 1 in the lysate is in a small latent
complex. However. as shown in Figure lb. by a Western
blot using anti-LTBP antibody. no LTBP band was
detected in the lysate obtained from KATO-III cells. These
results suggest that the TGF- I molecule in the cellular
extract of KATO-III is in a small latent complex of TGF-PI
and LAP.
Expression of TGF- 1 mRNA of KATO-III cells was
examined by Northern blot analysis. The RNA blot demon-
strated that KATO-III cells expressed a 2.5 kilobase trans-
cnpt of TGF-01 mRNA (Figure lc).
TGF-PI in cell lv sate ofKA TO-III
We have already reported that in the conditioned medium of
KATO-ITI. some appreciable amount of activated TGF-01
was present because it strongly promoted colony formation
of NRK-49F cells in soft agar and this TGF-PI activity was
suppressed by addition of anti-TGF-Pl antibodies (Mahara
et al.. 1994). These observations were obtained by another
more specific assay for TGF-p 1: the radioreceptor assay
(data was not shown). In order to elucidate whether the
TGF-jI1 of KATO-III cells is processed to become an active
form within the cell or is produced in a latent form and
then activated extracellularly. the intracellular form of
TGF-PI molecule was examined (Table I). Using the soft
agar colony assay. untreated KATO-II cell lysate showed
extremely weak activity of TGF- 1. while after acid treat-
ment. substantially higher activity appeared. On radiorecep-
tor assay. TGF-PI activity was below the limit of detection
for the untreated sample. but increased to 2.7 ng ml-' after
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Figure 1 Western blot analyses of TGF-Pl1 LAP and LTBP
and Northern blot analysis for TGF-Pl mRNA from KATO-III
cells. Each 10 lg of cellular extract of KATO-III cells was
electrophoresed under reducing conditions (a) or non-reducing
conditions (b) and the proteins were transferred to Immobilon
membranes as described in Materials and methods. Anti-TGF-
PI (a. lanes 1. 2) and anti-LAP (a. lane 3) antibodies were probed
respectively. TGF-PI was detected at a molecular mass of 52.5
kDa before treatment with acid-ethanol (a. lane 1). A band of
TGF-Pl at a molecular mass of 12.5 kDa was detected after
acid-ethanol treatment (a. lane 2). LAP was detected at a
molecular mass of 52.5 kDa without treatment of acid-ethanol
(a. lane 3). No expression of LTBP in the cell lysate of KATO-
III was detected by Western blotting using anti-LTBP antibody
(b. lane 2). The lysate of human platelets expressing LTBP was
loaded as a positive control (b. lane 1). TGF-Pl mRNA expres-
sion was analysed by Northern blot analysis as described in
Materials and methods. A 2.5 kb transcript of TGF-Pl mRNA
was detected (c).
Table 1 TGF-PI actiVity of KATO-III cell lvsate
Methods
Colon! assai Radioreceptor assa!
Treatment (colonies per wellb ngml-')
None 10 3a ND
Acidification 620 + 84 27 ± 0.7
Acidification 50 ± 14 ND
+ anti-TGF- 1 antibodies
TGF-P1I activity was measured by soft-agar colony assay and radioreceptor assav
as described in Materials and methods. TGF-P1 activity of50fig ofKATO-III cells
lvsate was measured in the presence or absence ofanti-TGF-P1 antibodies. aData are
expressed as the mean ± s.d. ND. Not detected.TGF-p1 actiaio-d d gashic cancr ci
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acid treatment in good agreement with the results of the
soft agar colony assay. Moreover, these activities were
significantly suppressed by the addition of anti-TGF-pl
neutralising antibodies. These results indicate that TGF-01
in KATO-III cells is in a latent form.
The gel chromatography ofKATO III cell lysate
KATO-I1I cell lysate was fractionated on gel chromato-
graphy and the TGF-PI activity of each fraction was
measured by radioreceptor assay (Figure 2). Non-acidified
samples revealed several small peaks of activity, possibly
representing the partial conversion of latent forms to active
forms during the preparation of cell lysate and the
chromatographic procedure by putative concomitant pro-
teases as suggested by Wakefield et al. (1988). Among the
small peaks, the most prominent one was assumed to be
that of mature TGF-PI since it was eluted at a fraction of
molecular weight of 25000 Da. In acidified samples, on the
other hand, three new distinct peaks of activity appeared in
relatively higher molecular weight fractions. The first peak
at the void volume might be an aggregated form. The
second main peak with molecular weight of 100 000 Da
apparently corresponded to the small latent TGF-01 com-
plex. These results indicate that TGF-PI in KATO-III cells
is produced in a small latent form which was consistent
with the results of Western blot analyses (Figure la and b).
Identification ofTGF-PI activator releasedbk KATO-III
cells
The fact that TGF-PI produced by KATO-III cells is pres-
ent in a latent form within the cells but in an active form in
the conditioned medium suggests either the presence of
some co-factor which activates latent TGF-PI after it is
secreted into the conditioned medium or an activation of
TGF-PI during the secretion process. To examine these
possibilities, conditioned medium from KATO-III cells was
fractionated on gel chromatography (Figure 3a) and each
fraction was added to conditioned medium from NRK49F
cells containing latent TGF-PI (Figure 3b). As shown in
Figure 3b, three major peaks of TGF-PI activity were
obtained and the first peak was eluted at the void volume,
the second at around a molecular weight of 65 000 Da, and
the third peak with smaller shoulder at a molecular weight
of 25 000 Da.
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Figure 2 Gel filtration profile of TGF-pl activity of KATO-III
cell lysate. An aliquot of 25 mg of KATO-III cell lysate was
subjected to gel chromatography. TGF-PI activity of each frac-
tion (0.5 ml per fraction) was determined by radioreceptor assay
before treatment (0) or after acid treatment (A). TGF-pI
activity (A) was also measured after treatment with the TGF-flI
activator (indicated by hatched area in Figure 3b) derived from
KATO-III cells.
Figure 3 Gel filtration profiles of TGF-Pl activity and TGF-PI
activator of conditioned medium obtained from KATO-III cells.
The conditioned medium was applied onto SW3000 column
chromatography, and TGF-p I activity of each fraction was
deter-mined by soft agar colony assay (a). Each fraction was
incubated with latent form TGF-Pl in the conditioned medium
obtained from NRK-49F cells and the remaining TGF-PI
activity was determined. The hatched area indicates the frac-
tions which activated the latent form TGF-PI (b). Each fraction
in b was treated with anti-TGF-Pl neutralising antibodies
before the colony assay (c).
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When the fractions of gel chromatography were tested for
TGF-PI activity in the absence of NRK-49F medium, only
two peaks at the void volume (peak 1) and at 25 000 Da
(peak 3), were obtained which each appeared to represent
an aggregated form and a mature form of TGF-f1 respec-
tively, (Figure 3a). Moreover, TGF-P1 activity in peak 2
(Figure 3b) was neutralised by anti-TGF-Pl antibodies
(Figure 3c). It was therefore assumed that the fraction
corresponding to peak 2 (-65 000) contained some factor
which activated latent TGF-P1 from NRK-49F cells. This
assumption was further confirmed by the fact that fractions
containing peak 2 were able to activate as effectively as acid
treatment, the latent TGF-P1 of KATO-III cell lysate fract-
ionated on gel chromatography (Figure 2). We therefore
designated the fraction (peak 2. Figure 3b) as a TGF-Pl
activator which strongly activated latent TGF-i1 from
KATO-III or NRK-49F cells.
Physicochemicalproperties andenzYmatic analtses ofthe
TGF-PI activator
We attempted the characterisation of the TGF-PI activator
from KATO-III cells by physicochemical and enzymatic
treatment. The TGF-P1 activator in the peak 2 fraction in
Figure 3b was partially inactivated by heat treatment at
56°C for 30 min or by acidification and completely by heat
treatment at 100'C for 5 min. Inactivation of the factor was
also brought about by treatment with trypsin, with
nafamostat mesilate. a synthetic senine protease inhibitor
and with DFP and PMSF, senine protease inhibitors. How-
ever, the activity of this factor was unaffected by treatment
with pepstatin, an aspartase protease inhibitor, with EDTA.
a metalloprotease inhibitor and with a2-plasmin inhibitor
(Table II). Neither plasmin nor plasminogen activator
activity was detected in the conditioned medium from
KATO-I1I cells. Moreover, the TGF-PI activator from
KATO-III cells did not convert plasminogen to plasmin in
the conditioned medium of NRK-49F cells (Table III).
Furthermore, this activator is more effective than some
enzymes including plasmin. cathepsin D, endoglycosidase F
or sialidase which have been reported as partial activators
for latent TGF-B1 (Table IV). These results suggest that the
TGF-PI activator is an acid and heat-labile serine protease,
different from plasmin. plasminogen activator. cathepsin D,
endoglycosidase F or sialidase.
Discussion
TGF-P1 produced by cells or platelets is generally inactive
and is somehow- conx-erted into an activ-e form at the site
where it functions. Ho"ever. in some types of cells. partic-
ularl- in tumour cells. TGF-PI is found to be active in their
conditioned medium and therefore can participate locally in
Table II Physicochemical properties of TGF-Pl activator in the
conditioned medium from KATO-111 cells
TGF-PI activity
Treatment (0% ofcontrol)
No treatment (control) lIOa
56C. 30 min 37.5
100°C. 5 min 0
pH 1.5. 2 h 30
pH 4.0. 2 h 37.5
Trypsin (0.25°0o) 0
Nafamostat mesilate (1 m- ) 0
DFP (1 mM) 0
PMSF (1 mM) 0
2-ethylmaleimide (0.5 mM) 89.4
Pepstatin (2 Lg ml-') 100
EDTA (2 mM) 100
c.-Plasmin inhibitor (1.0 Uml-') 100
2TGF-PI activity was measured by radioreceptor assay asdescribed in
Materials and methods.
various pathological situations such as myelofibrosis in acute
megakaryoblastic leukaemia (Terui et al.. 1990). stromal
induction in scirrhous gastric carcinoma (Mahara et al..
1994: Yoshida et al.. 1989). autocrine growth and hypercal-
caemia in adult T-cell leukaemia (Niitsu et al.. 1988) and
immunosuppression in glioblastoma (Wrann et al.. 1987).
However, whether the active TGF-PI in these media is indeed
secreted from tumour cells as it is or is converted from a
latent form by concomitantly secreted modulators (most
plausibly some enzymes) is still unclear.
We attempted to elucidate the above question using the
KATO-I1I cell hne of human gastric cancer. We (Mahara et
al.. 1994) and Ura et al. (1991) have already suggested the
presence of active TGF-PI in conditioned medium from
KATO-1I. because this conditioned medium promoted col-
ony formation of NRK-49F cells in soft agar. However. the
enhancement of colony formation is a phenomenon mani-
fested not only by TGF-PI but also by platelet-derived
growth factor (Van Zoelen et al.. 1985) and transforming
growth factor a (Derynk. 1988; Rosenthal et al.. 1988).
Therefore, in the present study. we first proved that the
activity of KATO-III conditioned medium manifested in the
soft-agar colony assay was TGF-P1 by employing a radio-
receptor assay (Table I) and by using neutralising anti-TGF-
P1 antibodies. Next, the question of whether TGF-P1 is
produced intracellularly in an active form or in a latent form
in KATO-III cells was investigated. From the results of the
radioreceptor assay of KATO-III cell lysate. intracellular
TGF-PI was shown to be mainly in the latent form (Table I).
With regard to the intracellular TGF-Bl. two different types
of latent form have been so far identified (Miyazono et al..
1988: Wakefield et al.. 1988. 1989: Takiuchi et al.. 1992). The
one is a large latent TGF-PI complex (235 000 Da) which is
composed of mature TGF-P1 (25 000 Da as a dimer), LAP
(80000Da as a dimer) and LTBP (130000-160000Da).
and the other is a small latent TGF-PI complex
(100 000 Da). which is composed of mature TGF-P1 and
LAP. The former has been found in human and rat platelets
and the latter was obtained as recombinant products from
TGF-PI gene-transfected cells. However, little is known
about the molecular form of latent TGF-P1 in tumour cells.
Therefore. we conducted immunoblot analyses using
antibodies for TGF-p1. LAP and LTBP. The data showed
Table III Plasmin activity of TGF-pI activator in the conditioned
medium from KATO-III cells
Plasmin activity
Samples (A.05 min'
TGF-PI activator <0.00 a
TGF-PI activator
+ NRK conditioned medium <0.001
TGF-P1 activator <0.001
+ Plasminogen
Plasmin (0.05 U ml-') 0.091
Plasmin (0.025 U ml ') 0.023
3Plasmin activitv was measured as described in Matenrals and
methods.
Table IV Activation of latent TGF-PI in the conditioned medium
from NRK cells by vanrous treatments
Treatment
TGF-PI activitya
(ngml-')
No treatment <0.05
Acidificationb 4.3 ± 0.3'
TGF-PI activator (50 yig ml-') 4.0 ± 0.3
Plasmin (1.0 U ml-') 1.3 0.2
Cathepsin D (0.3 U ml-') 0.7 ± 0.1
Sialidase (0.5 U ml ') 0.2 0.1
Endoglycosidase F (0.5 U ml ') <0.05
'TGF-PI activity was measured by ELISA as described in Materials
and methods bConditioned medium was treated with 0.03 N hydro-
chlonrc acid for 1 h at 4°C. cData are expressed as the means ± s.d.TGq activAmderived gastriccafxcerl
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that TGF-Bl protein in the lysate obtained from KATO-III
cells was an uncleaved complex of TGF-P1 and LAP. How-
ever. LTBP was not detected in the lysate of KATO-III cells.
Taken together. this suggested that TGF-Pl in the lysate of
KATO-III cells existed in a small latent form. This outcome
is also consistent with the results of gel chromatography. It
has been reported that in human platelets (Wakefield et al..
1988) and in Chinese hamster ovary (CHO) cells transfected
with the pro-TGF-Pl gene (Gentry et al., 1987), latent TGF-
P1 was partially separated into mature TGF-PI and LAP in
the presence of SDS. However. in our experiment. we were
not able to demonstrate mature TGF-P1 in the lysate of
KATO-ITI by SDS-PAGE. The apparent discrepancy
between the results of previous reports and ours may be
simply explained by postulating that in our particular cells
cleavage of latent TGF-PI to yield mature TGF-PI barely
occurred. and that the mature TGF-P1 was undetectable on
SDS-PAGE.
Mizoi et al. (1993) recently reported that LTBP was not
observed in gastric cancer cells. Our results are consistent
with this. Taking into account the fact that TGF-PI in
KATO-III cells exists intracellularly in a latent form and
extracellularlv in an active form, the possible presence of a
factor which activates latent TGF-PI in conditioned medium
was then investigated. Gel chromatography of the condit-
ioned medium from KATO-III cells revealed that it con-
tained a factor of molecular weight of approximately
65 000 Da which activates latent TGF-PI derived from NRK-
49F cells (Figure 3b). Moreover. this fraction actually
activated latent TGF-PI in KATO-III cell lysate as effectively
as acid treatment (Figure 2). Therefore. TGF-Pl produced by
KATO-I1I cells appears to be synthesised and secreted in a
latent form and then converted to an active form by a
TGF-P1 activator simultaneously released by the tumour
cells.
Various types of enzymes including plasmin (Lyons et al..
1988: Sato and Riflin. 1989). cathepsin D (Lyons et al.. 1988).
endoglycosidase F and sialidase (Miyazono and Heldin.
1988) have been proposed as authentic activators for latent
TGF-pl. although none of these have been actually
identified in the culture medium of tumour cells which
secrete TGF-pl.
In this report. we demonstrated for the first time a factor
in conditioned medium from KATO-III cells which acti-
vates latent TGF-PI as effectively as acid treatment (Figure
2, Table IV). This factor was inactivated by treatment with
heat, acidification, trypsin. or a synthetic senne protease
inhibitor. nafamostat mesilate, indicating it is a type of
protease. Moreover, treatment with serine protease in-
hibitors such as DFP or PMSF resulted in inactivation.
whereas no inactivation was observed with treatment by
other protease inhibitors such as N-ethylmaleimide, pep-
statin and EDTA. suggesting that the factor is a type of
serine protease. Further, since no changes in activity
resulted from treatment with m-plasmin inhibitor and no
plasmin activity was detected in the supernatant. the factor
is different from plasmin which previously has been
identified as a potent TGF-PI activator or plasminogen
activator. More detailed studies including purification and
characterisation of the TGF-P1 activator will permit deter-
mination of the mechanism necessary to activate latent
TGF-pl.
In conclusion, we demonstrated that the KATO-I1I cells
derived from human gastric carcinoma produce and release
small latent TGF-P1 together with a senine protease, diff-
erent from plasmin. plasminogen activator, cathepsin D.
endoglycosidase or sialidase which alters this latent TGF-PI
extracellularly to the active form as effectively as acid treat-
ment.
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